How does Pazopanib actually stop cancer from growing?
Pazopanib blocks eight different growth-signal receptors (VEGFR, PDGFR, FGFR, Kit) that tumors use to build new blood vessels and spread. In the PALETTE trial, patients on Pazopanib lived 4.6 months without cancer progression versus 1.6 months on placebo—a 3-month improvement. [2]
Tumors are like tiny cities that need blood vessels to survive and grow. Pazopanib acts like a traffic cop, blocking the chemical signals (called tyrosine kinases) that tell blood vessels to form around cancer cells. In the PALETTE soft-tissue sarcoma trial, 20% more patients on Pazopanib stayed cancer-free longer than those on placebo. [2]
Inside your body, Pazopanib travels through your bloodstream and enters cancer cells, where it sticks to eight different receptor proteins and shuts them down. Think of it like turning off eight light switches at once—the tumor can't send out its "grow and spread" signals anymore. Your immune system then has a better chance to clean up the weakened cancer cells. [2][9]
The trade-off is that Pazopanib also affects normal blood vessels and liver cells, which is why monthly liver blood tests are mandatory. If your ALT (a liver enzyme) climbs above three times the normal limit, your oncologist will pause the drug or lower your dose. Catching liver injury early prevents serious damage. [9]
Ask your oncologist: "What's my baseline ALT and AST, and when is my first follow-up blood test?" Write down the date and set a phone reminder—missing a liver check can delay your treatment plan.